Search Results - "Posvar, E L"

  • Showing 1 - 19 results of 19
Refine Results
  1. 1

    Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects by Cilla, Jr, D D, Whitfield, L R, Gibson, D M, Sedman, A J, Posvar, E L

    Published in Clinical pharmacology and therapeutics (01-12-1996)
    “…This study examined the pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an investigational inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A…”
    Get more information
    Journal Article
  2. 2

    Single-Dose Gabapentin Pharmacokinetics and Safety in Healthy Infants and Children by Haig, George M., Bockbrader, Howard N., Wesche, David L., Boellner, Samuel W., Ouellet, Daniele, Brown, Richard R., Randinitis, Edward J., Posvar, Edward L.

    Published in Journal of clinical pharmacology (01-05-2001)
    “…Gabapentin (Neurontin®) is a gamma‐aminobutyric acid analogue indicated in adults for adjunctive treatment of partial seizures with or without secondary…”
    Get full text
    Journal Article
  3. 3

    Quinapril and its metabolite quinaprilat in human milk by Begg, E. J., Robson, R. A., Gardiner, S. J., Hudson, L. J., Reece, P. A., Olson, S. C., Posvar, E. L., Sedman, A. J.

    Published in British journal of clinical pharmacology (01-05-2001)
    “…Aims  To measure the milk to plasma ratio (M/P) of quinapril and its active metabolite quinaprilat in lactating mothers and to assess likely infant exposure…”
    Get full text
    Journal Article
  4. 4

    Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects by Posvar, E L, Radulovic, L L, Cilla, Jr, D D, Whitfield, L R, Sedman, A J

    Published in Journal of clinical pharmacology (01-08-1996)
    “…Tolerance and pharmacokinetics after single-dose administration of atorvastatin, an investigational inhibitor of HMG-CoA reductase, were examined in 22 healthy…”
    Get more information
    Journal Article
  5. 5

    Effect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitor by Radulovic, L L, Cilla, D D, Posvar, E L, Sedman, A J, Whitfield, L R

    Published in Journal of clinical pharmacology (01-10-1995)
    “…To determine whether atorvastatin, a new HMG-CoA reductase inhibitor, could be administered with food in Phase II and III clinical trials, a nonblind,…”
    Get more information
    Journal Article
  6. 6

    Lack of interaction of gabapentin with carbamazepine or valproate by Radulovic, L L, Wilder, B J, Leppik, I E, Bockbrader, H N, Chang, T, Posvar, E L, Sedman, A J, Uthman, B M, Erdman, G R

    Published in Epilepsia (Copenhagen) (01-01-1994)
    “…Gabapentin (GBP) studies were conducted in patients with epilepsy receiving carbamazepine (CBZ, n = 12) or valproate (VPA, n = 14) monotherapy. The effects of…”
    Get more information
    Journal Article
  7. 7
  8. 8

    The temporal effect of food on tacrine bioavailability by Welty, D F, Siedlik, P H, Posvar, E L, Selen, A, Sedman, A J

    Published in Journal of clinical pharmacology (01-10-1994)
    “…A four-way cross-over study was performed to assess the temporal effect of food on the rate and extent of tacrine (Cognex, THA) absorption after drug…”
    Get more information
    Journal Article
  9. 9

    Hemodynamic and hormonal effects of quinaprilat in patients with congestive heart failure by Mitrovic, V, Mudra, H, Bonzel, T, Schmidt, W, Strand, J C, Bakovic-Alt, R, Posvar, E L

    Published in Clinical pharmacology and therapeutics (01-06-1996)
    “…To assess the pharmacodynamic activity and safety of rising single and multiple doses of intravenous quinaprilat compared with placebo in patients with New…”
    Get more information
    Journal Article
  10. 10

    Pharmacokinetics of quinapril and its active metabolite quinaprilat during continuous ambulatory peritoneal dialysis by Swartz, R D, Starmann, B, Horvath, A M, Olson, S C, Posvar, E L

    Published in Journal of clinical pharmacology (01-12-1990)
    “…The pharmacokinetics of quinapril, a novel angiotensin converting enzyme (ACE) inhibitor, and its active metabolite, quinaprilat, were determined following a…”
    Get more information
    Journal Article
  11. 11

    Pharmacokinetics of quinapril and its active metabolite, quinaprilat, in patients on chronic hemodialysis by Blum, R A, Olson, S C, Kohli, R K, Horvath, A M, Sedman, A J, Posvar, E L

    Published in Journal of clinical pharmacology (01-10-1990)
    “…The pharmacokinetics of quinapril and its active metabolite, quinaprilat, were evaluated in 12 patients with end-stage renal disease (ESRD) on chronic…”
    Get more information
    Journal Article
  12. 12
  13. 13

    The pharmacokinetics of quinapril and quinaprilat in patients with congestive heart failure by Begg, EJ, Robson, RA, Ikram, H, Richards, AM, Bammert‐Adams, JA, Olson, SC, Posvar, EL, Reece, PA, Sedman, AJ

    Published in British journal of clinical pharmacology (01-03-1994)
    “…The pharmacokinetics of quinapril and its active metabolite quinaprilat were studied in 12 patients with congestive heart failure (CHF) after multiple oral…”
    Get full text
    Journal Article
  14. 14

    ACE inhibitors in the elderly by Posvar, E L, Sedman, A J

    Published in Angiology (01-05-1991)
    “…As the population with hypertension becomes older, it is important to determine the properties of angiotensin-converting enzyme (ACE) inhibitors in the…”
    Get more information
    Journal Article
  15. 15

    The pharmacokinetics of quinapril and its active metabolite, quinaprilat, in patients with various degrees of renal function by Halstenson, C E, Opsahl, J A, Rachael, K, Olson, S C, Horvath, A M, Abraham, P A, Posvar, E L

    Published in Journal of clinical pharmacology (01-04-1992)
    “…Single- and multiple-dose pharmacokinetics of quinapril and its active metabolite, quinaprilat, were determined after oral administration of 20 mg quinapril…”
    Get more information
    Journal Article
  16. 16

    Evaluation of quinapril on regional blood flow and cardiac function in patients with congestive heart failure by Munger, M A, Chance, M, Nair, R, Prescott, A W, Nara, A R, Simonson, M S, Green, J A, Posvar, E L

    Published in Journal of clinical pharmacology (01-01-1992)
    “…Quinapril, a nonsulfhydryl ACE inhibitor, was evaluated in ten New York Heart Association (NYHA) functional class (FC) II-III CHF patients to determine its…”
    Get more information
    Journal Article
  17. 17

    Minimal androgenic activity of a new oral contraceptive containing norethindrone acetate and graduated doses of ethinyl estradiol by Boyd, Rebecca A, Zegarac, Elizabeth A, Posvar, Edward L, Flack, Mary R

    Published in Contraception (Stoneham) (01-02-2001)
    “…The pharmacokinetics and androgenic activity of Estrostep ®, a new oral contraceptive providing low-dose estrogen in a graduated sequence with a constant dose…”
    Get full text
    Journal Article
  18. 18

    Clinical Pharmacokinetics of Pregabalin in Healthy Volunteers by Bockbrader, Howard N., Radulovic, Louis L., Posvar, Edward L., Strand, James C., Alvey, Christine W., Busch, Janice A., Randinitis, Edward J., Corrigan, Brian W., Haig, George M., Boyd, Rebecca A., Wesche, David L.

    Published in Journal of clinical pharmacology (01-08-2010)
    “…Pregabalin has shown clinical efficacy for treatment of neuropathic pain syndromes, partial seizures, and anxiety disorders. Five studies in healthy volunteers…”
    Get full text
    Journal Article
  19. 19

    Pharmacokinetics of Pregabalin in Subjects with Various Degrees of Renal Function by Randinitis, Edward J., Posvar, Edward L., Alvey, Christine W., Sedman, Allen J., Cook, Jack A., Bockbrader, Howard N.

    Published in Journal of clinical pharmacology (01-03-2003)
    “…The objectives of this study were to determine the single‐dose pharmacokinetics of pregabalin in subjects with various degrees of renal function, determine the…”
    Get full text
    Journal Article